Tag Archives: NASDAQ:IOVA

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA) and Neuronetics (NASDAQ: STIM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iovance Biotherapeutics (IOVA – Research Report) and Neuronetics (STIM – Research Report) with bullish sentiments. Iovance Biotherapeutics (IOVA) Oppenheimer analyst Mark Breidenbach

Oppenheimer Gives a Buy Rating to Iovance Biotherapeutics (IOVA)

Oppenheimer analyst Mark Breidenbach assigned a Buy rating to Iovance Biotherapeutics (IOVA – Research Report) yesterday and set a price target of $43.00. The company’s shares closed last Thursday at $31.15. According to TipRanks.com, Breidenbach is a 5-star analyst with

Analysts Are Bullish on Top Healthcare Stocks: Iovance Biotherapeutics (IOVA), Celsion (CLSN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iovance Biotherapeutics (IOVA – Research Report) and Celsion (CLSN – Research Report) with bullish sentiments. Iovance Biotherapeutics (IOVA) Chardan Capital analyst Geulah

Mizuho Securities Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)

In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report), with a price target of $61.00. The company’s shares closed last Tuesday at $32.66. According to TipRanks.com, Goldstein is

Iovance Biotherapeutics (IOVA) Gets a Buy Rating from Chardan Capital

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Iovance Biotherapeutics (IOVA – Research Report) today and set a price target of $44.00. The company’s shares closed last Tuesday at $33.84. According to TipRanks.com, Livshits is a 4-star analyst

Mizuho Securities Believes Iovance Biotherapeutics (NASDAQ: IOVA) Still Has Room to Grow

Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Iovance Biotherapeutics (IOVA – Research Report) today and set a price target of $61.00. The company’s shares closed last Friday at $36.91, close to its 52-week high of $39.00. According